China Gliquidone Market Investigation Report 2010-2019

News provided by

Aug 17, 2015, 09:20 ET

DUBLIN, Aug. 17, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/8kh77c/investigation) has announced the addition of the "Investigation Report on China's Gliquidone Market, 2010-2019" report to their offering.

It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). The IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while in America it will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.

As one of the earliest oral antidiabetic drugs, sulfonylurea is common to patients with insulin hyposecretion. By stimulating insulin secretion, sulfonylurea is able to reduce blood glucose. According to the length of action, sulfonylurea can be categorized into short-acting, medium-acting and long-acting preparations. And glibenclamide, gliquidone, gliclazide and glimepiride are the common drugs in the class of sulfonylurea.

Developed by Boehringer-Ingelheim, gliquidone first came into the German market in 1975 under the trade name of Glurenorm. As the main metabolite of gliquidone is eliminated from the body with bile and only 5% is excreted renally, i.e. hardly influenced by the glomerular filtration rate (GFR), drug metabolism can ease the kidney's burden and therefore is more suitable for patients with damaged renal function. Gliguidone is with good tolerance and few side effects are common for patients and few, if any, patients will have a skin allergy, gastrointestinal discomfort and sensation of vertigo. If guiguidone alone doesn't work, metformin could be added in the treatment.

As gliquidone is expelled from the body with bile after being metabolized by CYP3A4 enzyme system in the liver and only 6% of it is excreted through the kidneys, it is more suitable for patients with kidney disorders.
In 1990, gliquidone co-produced by Boehringer-Ingelheim and Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd entered China under the trade name of Glurenorm. And in 1997, gliquidone developed by TIPR Pharmaceutical Responsible Co., Ltd came into the market under the trade name of Jieshi. Apart from the above-mentioned two products, other products are also available in the Chinese market.

According to this market survey, in 2014, Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd took up a market share of about 97% for sales value in China while other companies like TIPR Pharmaceutical Responsible Co., Ltd, Jiangsu Vanguard Pharmaceutical Co., Ltd and Jilin Jinheng Pharmaceutical Co., Ltd and Shijiazhuang Yiling Pharmaceutical Co., Ltd shared the rest of the market share. The annual sales value of gliquidone in sample hospitals stayed at CNY 40 million in recent years.

Key Topics Covered:

1 Related Concepts of Gliquidone

2 Market Profile of Gliquidone in China

3 Survey on Sales Status of Gliquidone in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Gliquidone in China, 2010-2014

5 Survey on Dosage Forms of Gliquidone in China, 2010-2014

6 Reference Price of Gliquidone in Chinese Hospitals in 2014

7 Major Manufacturers of Gliquidone in Chinese Market, 2010-2014

8 Market Outlook of Gliquidone in China, 2015-2019

Companies Mentioned

- Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd
- Jiangsu Vanguard Pharmaceutical Co., Ltd
- Jilin Jinheng Pharmaceutical Co., Ltd
- Shijiazhuang Yiling Pharmaceutical Co., Ltd
- TIPR Pharmaceutical Responsible Co., Ltd

For more information visit http://www.researchandmarkets.com/research/8kh77c/investigation